We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Good and Motic Announce AI-Powered Microscope at MEDICA 2017

By LabMedica International staff writers
Posted on 15 Nov 2017
Print article
Image: The EasyScan GO AI-powered microscope is designed to help fight the spread of drug-resistant malaria and assist in case management (Photo courtesy of Motic).
Image: The EasyScan GO AI-powered microscope is designed to help fight the spread of drug-resistant malaria and assist in case management (Photo courtesy of Motic).
Advanced microscope designer and manufacturer Motic China Group Co., Ltd. (Xiamen, China), has announced at MEDICA 2017 that it will partner with the Global Good Fund (Bellevue, WA, USA), a collaboration between Intellectual Ventures and Bill Gates, to develop technologies for humanitarian impact. The collaboration will create and distribute the EasyScan GO, a breakthrough AI-powered microscope to fight the spread of drug-resistant malaria and assist in case management.

Motic specializes in manufacturing conventional compound microscopes, while Global Good is dedicated to inventing technology for humanitarian impact by collaborating with leading humanitarian organizations, forward-looking governments, research institutions, and corporate and private sector partners. Both Motic and Global Good will collaborate to create and distribute the EasyScan GO AI-powered microscope, which uses custom image recognition software to identify and count malaria parasites in a blood smear in as little as 20 minutes.

Accurate detection of severe and drug-resistant cases requires analysis of a blood smear by a WHO-certified expert microscopist, which takes roughly 20 minutes per slide. Automating the process with an intelligent microscope can alleviate the shortfall of trained personnel in under-resourced countries. Field tests of an early prototype of the microscope presented at the International Conference on Computer Vision (ICCV) showed that the machine-learning algorithm developed by Global Good is as reliable as an expert microscopist.

The EasyScan GO is currently being trained to recognize all species of malaria and other parasites and traits commonly found on a blood film, including Chagas disease, microfilaria and sickle cell. The team will also explore its application to other sample types, such as sputum, feces and tissue, as well some forms of cancer.

“This collaboration, combining Global Good’s impact invention focus with Motic’s engineering, manufacturing and distribution capabilities, represents the type of innovative healthcare solution that is needed to improve health in emerging and low-income markets,” said Maurizio Vecchione, Intellectual Ventures’ Executive Vice President of Global Good and Research. “By distributing and commercializing an intelligent microscope, Global Good and Motic are creating a future where quality diagnosis of multiple diseases is within reach for everyone everywhere.”

“Malaria is one of the hardest diseases to identify on a microscope slide,” said David Bell, Director of Global Health Technologies supporting Global Good. “By putting machine learning-enabled microscopes in the hands of laboratory technicians, we can overcome two major barriers to combating the mutating parasite—improving diagnosis in case management and standardizing detection across geographies and time.”

“Our goal in integrating Global Good’s advanced software into Motic’s high-quality, affordable digital slide scanner is to simplify and standardize malaria detection,” said Richard Yeung, Vice President of Motic China. “Success with the most difficult-to-identify disease paves the way for the EasyScan product line to excel at almost any microscopy task and to detect other major diseases that affect developed and emerging markets alike.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more